Merck & Co Target of Unusually Large Options Trading (MRK)
Shares of Merck & Co (NYSE:MRK) was the recipient of some unusual options trading on Monday. Traders bought 18,647 put options on the stock, StockRatingsNetwork.com reports. This is an increase of 251% compared to the average daily volume of 5,312 put options.
MRK has been the subject of a number of recent research reports. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Monday. Separately, analysts at Jefferies Group raised their price target on shares of Merck & Co from $51.00 to $54.00 in a research note to investors on Thursday, January 9th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note to investors on Tuesday, December 31st. They now have a $52.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $52.24.
Merck & Co (NYSE:MRK) opened at 53.12 on Tuesday. Merck & Co has a 1-year low of $40.83 and a 1-year high of $53.44. The stock has a 50-day moving average of $49.50 and a 200-day moving average of $48.00. The company has a market cap of $155.2 billion and a price-to-earnings ratio of 33.52.
Merck & Co (NYSE:MRK) last announced its earnings results on Monday, October 28th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.04. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. Analysts expect that Merck & Co will post $3.50 EPS for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.